Aeglea Acquires
Spyre Therapeutics

Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a world-class inflammatory bowel disease (IBD) portfolio.

View Press Release

3

Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a world-class inflammatory bowel disease (IBD) portfolio.

Read Press Release

Transforming the Treatment of Inflammatory Bowel Disease

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.

Learn More About Spyre

Transforming the Treatment of IBD

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.

Learn More About Spyre